300 related articles for article (PubMed ID: 27067724)
21. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Honciuc M; Llorca PM
Encephale; 2015 Dec; 41(6):541-9. PubMed ID: 26603973
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M; Greene M; Touya M; Sweeney SM; Waters H
J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
[TBL] [Abstract][Full Text] [Related]
23. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis.
Lin L; Zhao YJ; Zhou HJ; Khoo AL; Teng M; Soh LB; Lim BP; Sim K
Int Clin Psychopharmacol; 2016 Mar; 31(2):84-92. PubMed ID: 26619182
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
Goldman R; Loebel A; Cucchiaro J; Deng L; Findling RL
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):516-525. PubMed ID: 28475373
[TBL] [Abstract][Full Text] [Related]
25. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
Tandon R; Cucchiaro J; Phillips D; Hernandez D; Mao Y; Pikalov A; Loebel A
J Psychopharmacol; 2016 Jan; 30(1):69-77. PubMed ID: 26645209
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study.
King D; Knapp M; Thomas P; Razzouk D; Loze JY; Kan HJ; van Baardewijk M
Curr Med Res Opin; 2011 Feb; 27(2):365-74. PubMed ID: 21166610
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Park T; Kuntz KM
Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
[TBL] [Abstract][Full Text] [Related]
29. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of paliperidone extended release in Spain.
Treur M; Baca E; Bobes J; Cañas F; Salvador L; Gonzalez B; Heeg B
J Med Econ; 2012; 15 Suppl 1():26-34. PubMed ID: 23016569
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review.
Henrique ICB; de Mendonça Lima T; de Melo DO; Aguiar PM
J Clin Pharm Ther; 2020 Feb; 45(1):1-15. PubMed ID: 31436857
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Ascher-Svanum H; Stensland MD; Peng X; Faries DE; Stauffer VL; Osuntokun OO; Kane JM
Curr Med Res Opin; 2011 Jan; 27(1):115-22. PubMed ID: 21110749
[TBL] [Abstract][Full Text] [Related]
34. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness and Price of Aripiprazole for Schizophrenia in the Brazilian Public Health System.
Soares Santos A; de Souza Noronha KVM; Viegas Andrade M; Mariano Ruas C
J Ment Health Policy Econ; 2020 Mar; 23(1):27-37. PubMed ID: 32458815
[TBL] [Abstract][Full Text] [Related]
36. Lurasidone for schizophrenia.
Drug Ther Bull; 2015 Mar; 53(3):30-2. PubMed ID: 25765597
[TBL] [Abstract][Full Text] [Related]
37. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Kasteng F; Eriksson J; Sennfält K; Lindgren P
Acta Psychiatr Scand; 2011 Sep; 124(3):214-25. PubMed ID: 21609324
[TBL] [Abstract][Full Text] [Related]
38. Cost analysis of the adverse reactions of bipolar disorder treatment with aripiprazole and olanzapine in Spain.
Rubio-Terrés C; Rubio-Rodríguez D; Baca-Baldomero E
Actas Esp Psiquiatr; 2014; 42(5):242-9. PubMed ID: 25179096
[TBL] [Abstract][Full Text] [Related]
39. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.
Graham CN; Mauskopf JA; Lawson AH; Ascher-Svanum H; Bruhn D
Value Health; 2012 Jan; 15(1):55-64. PubMed ID: 22264972
[TBL] [Abstract][Full Text] [Related]
40. Lurasidone in the treatment of schizophrenia: a critical evaluation.
Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
